Loading…

Identification and quantification of host cell protein impurities in biotherapeutics using mass spectrometry

Residual host cell proteins (HCPs) in biotherapeutics can present potential safety risks to patients or compromise product stability. As such, their levels are typically monitored using a multicomponent HCP enzyme-linked immunosorbent assay (ELISA) to ensure adequate removal. However, it is not poss...

Full description

Saved in:
Bibliographic Details
Published in:Analytical biochemistry 2012-09, Vol.428 (2), p.150-157
Main Authors: Schenauer, Matthew R., Flynn, Gregory C., Goetze, Andrew M.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c440t-8b280ec8c549ef37c3bda759a387e17bd268228453e88bd7f8322fccf1edbc733
cites cdi_FETCH-LOGICAL-c440t-8b280ec8c549ef37c3bda759a387e17bd268228453e88bd7f8322fccf1edbc733
container_end_page 157
container_issue 2
container_start_page 150
container_title Analytical biochemistry
container_volume 428
creator Schenauer, Matthew R.
Flynn, Gregory C.
Goetze, Andrew M.
description Residual host cell proteins (HCPs) in biotherapeutics can present potential safety risks to patients or compromise product stability. As such, their levels are typically monitored using a multicomponent HCP enzyme-linked immunosorbent assay (ELISA) to ensure adequate removal. However, it is not possible to guarantee ELISA coverage of every possible HCP impurity, and the specific HCPs remaining following purification are rarely identified. In the current study, we characterized the ability of an advanced two-dimensional liquid chromatography/mass spectrometry platform (2D–LC/MSE) to identify and quantify known low-level spiked protein impurities in a therapeutic peptide Fc fusion protein. The label-free quantification procedure based on the “top 3” intensity tryptic peptides per protein was applied and improved on for this application. Limits of detection for unknown HCPs were approximated from the spiked protein data along with estimates for the quantitative accuracy of the method. In all, we established that most protein impurities present at 13±4ppm can be identified with a quantitative error of less than 2-fold using the more sensitive of two tested method formats. To conclude the study, we characterized all detectable Escherichia coli proteins present in this Fc fusion protein drug substance and discuss future applications of the method.
doi_str_mv 10.1016/j.ab.2012.05.018
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1032888846</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0003269712002874</els_id><sourcerecordid>1032888846</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-8b280ec8c549ef37c3bda759a387e17bd268228453e88bd7f8322fccf1edbc733</originalsourceid><addsrcrecordid>eNp1kU1v1DAQhi0EotvCnRP4yCVhbCeOww1VUCpV4gA9W_6YtF5t4tR2KvXf49UWxAVfRraeeT16hpB3DFoGTH7at8a2HBhvoW-BqRdkx2CUDQgYX5IdAIiGy3E4I-c57wEY63r5mpxxLjuQ0O3I4drjUsIUnCkhLtQsnj5s5t-nONH7mAt1eDjQNcWCYaFhXrcUSsBM682GWO4xmRW3ElymWw7LHZ1NzjSv6EqKM5b09Ia8mswh49vnekFuv339dfm9uflxdX355aZxXQelUZYrQKdc3404icEJ683Qj0aoAdlgPZeKc9X1ApWyfpiU4HxybmLorRuEuCAfT7l12ocNc9FzyMfxzYJxy5qB4KqeTlYUTqhLMeeEk15TmE16qpA-OtZ7baw-OtbQ6-q4trx_Tt_sjP5vwx-pFfhwAiYTtblLIevbnzVBHvcBUkAlPp8IrBYeAyadXcDFoQ-p6tI-hv___xty2JdV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1032888846</pqid></control><display><type>article</type><title>Identification and quantification of host cell protein impurities in biotherapeutics using mass spectrometry</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Schenauer, Matthew R. ; Flynn, Gregory C. ; Goetze, Andrew M.</creator><creatorcontrib>Schenauer, Matthew R. ; Flynn, Gregory C. ; Goetze, Andrew M.</creatorcontrib><description>Residual host cell proteins (HCPs) in biotherapeutics can present potential safety risks to patients or compromise product stability. As such, their levels are typically monitored using a multicomponent HCP enzyme-linked immunosorbent assay (ELISA) to ensure adequate removal. However, it is not possible to guarantee ELISA coverage of every possible HCP impurity, and the specific HCPs remaining following purification are rarely identified. In the current study, we characterized the ability of an advanced two-dimensional liquid chromatography/mass spectrometry platform (2D–LC/MSE) to identify and quantify known low-level spiked protein impurities in a therapeutic peptide Fc fusion protein. The label-free quantification procedure based on the “top 3” intensity tryptic peptides per protein was applied and improved on for this application. Limits of detection for unknown HCPs were approximated from the spiked protein data along with estimates for the quantitative accuracy of the method. In all, we established that most protein impurities present at 13±4ppm can be identified with a quantitative error of less than 2-fold using the more sensitive of two tested method formats. To conclude the study, we characterized all detectable Escherichia coli proteins present in this Fc fusion protein drug substance and discuss future applications of the method.</description><identifier>ISSN: 0003-2697</identifier><identifier>EISSN: 1096-0309</identifier><identifier>DOI: 10.1016/j.ab.2012.05.018</identifier><identifier>PMID: 22640604</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Amino Acid Sequence ; Biological Therapy ; Chromatography, Liquid ; detection limit ; drugs ; enzyme-linked immunosorbent assay ; Escherichia coli ; Escherichia coli - metabolism ; Escherichia coli Proteins - metabolism ; Host cell proteins ; Humans ; liquid chromatography ; Mass spectrometry ; Mass Spectrometry - methods ; Molecular Sequence Data ; patients ; peptides ; Peptides - analysis ; Peptides - chemistry ; proteins ; Proteins - analysis ; Proteins - chemistry ; Quantification ; Receptors, Fc - metabolism ; Recombinant Fusion Proteins - metabolism ; Reference Standards ; risk</subject><ispartof>Analytical biochemistry, 2012-09, Vol.428 (2), p.150-157</ispartof><rights>2012 Elsevier Inc.</rights><rights>Copyright © 2012 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-8b280ec8c549ef37c3bda759a387e17bd268228453e88bd7f8322fccf1edbc733</citedby><cites>FETCH-LOGICAL-c440t-8b280ec8c549ef37c3bda759a387e17bd268228453e88bd7f8322fccf1edbc733</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22640604$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schenauer, Matthew R.</creatorcontrib><creatorcontrib>Flynn, Gregory C.</creatorcontrib><creatorcontrib>Goetze, Andrew M.</creatorcontrib><title>Identification and quantification of host cell protein impurities in biotherapeutics using mass spectrometry</title><title>Analytical biochemistry</title><addtitle>Anal Biochem</addtitle><description>Residual host cell proteins (HCPs) in biotherapeutics can present potential safety risks to patients or compromise product stability. As such, their levels are typically monitored using a multicomponent HCP enzyme-linked immunosorbent assay (ELISA) to ensure adequate removal. However, it is not possible to guarantee ELISA coverage of every possible HCP impurity, and the specific HCPs remaining following purification are rarely identified. In the current study, we characterized the ability of an advanced two-dimensional liquid chromatography/mass spectrometry platform (2D–LC/MSE) to identify and quantify known low-level spiked protein impurities in a therapeutic peptide Fc fusion protein. The label-free quantification procedure based on the “top 3” intensity tryptic peptides per protein was applied and improved on for this application. Limits of detection for unknown HCPs were approximated from the spiked protein data along with estimates for the quantitative accuracy of the method. In all, we established that most protein impurities present at 13±4ppm can be identified with a quantitative error of less than 2-fold using the more sensitive of two tested method formats. To conclude the study, we characterized all detectable Escherichia coli proteins present in this Fc fusion protein drug substance and discuss future applications of the method.</description><subject>Amino Acid Sequence</subject><subject>Biological Therapy</subject><subject>Chromatography, Liquid</subject><subject>detection limit</subject><subject>drugs</subject><subject>enzyme-linked immunosorbent assay</subject><subject>Escherichia coli</subject><subject>Escherichia coli - metabolism</subject><subject>Escherichia coli Proteins - metabolism</subject><subject>Host cell proteins</subject><subject>Humans</subject><subject>liquid chromatography</subject><subject>Mass spectrometry</subject><subject>Mass Spectrometry - methods</subject><subject>Molecular Sequence Data</subject><subject>patients</subject><subject>peptides</subject><subject>Peptides - analysis</subject><subject>Peptides - chemistry</subject><subject>proteins</subject><subject>Proteins - analysis</subject><subject>Proteins - chemistry</subject><subject>Quantification</subject><subject>Receptors, Fc - metabolism</subject><subject>Recombinant Fusion Proteins - metabolism</subject><subject>Reference Standards</subject><subject>risk</subject><issn>0003-2697</issn><issn>1096-0309</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp1kU1v1DAQhi0EotvCnRP4yCVhbCeOww1VUCpV4gA9W_6YtF5t4tR2KvXf49UWxAVfRraeeT16hpB3DFoGTH7at8a2HBhvoW-BqRdkx2CUDQgYX5IdAIiGy3E4I-c57wEY63r5mpxxLjuQ0O3I4drjUsIUnCkhLtQsnj5s5t-nONH7mAt1eDjQNcWCYaFhXrcUSsBM682GWO4xmRW3ElymWw7LHZ1NzjSv6EqKM5b09Ia8mswh49vnekFuv339dfm9uflxdX355aZxXQelUZYrQKdc3404icEJ683Qj0aoAdlgPZeKc9X1ApWyfpiU4HxybmLorRuEuCAfT7l12ocNc9FzyMfxzYJxy5qB4KqeTlYUTqhLMeeEk15TmE16qpA-OtZ7baw-OtbQ6-q4trx_Tt_sjP5vwx-pFfhwAiYTtblLIevbnzVBHvcBUkAlPp8IrBYeAyadXcDFoQ-p6tI-hv___xty2JdV</recordid><startdate>20120915</startdate><enddate>20120915</enddate><creator>Schenauer, Matthew R.</creator><creator>Flynn, Gregory C.</creator><creator>Goetze, Andrew M.</creator><general>Elsevier Inc</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120915</creationdate><title>Identification and quantification of host cell protein impurities in biotherapeutics using mass spectrometry</title><author>Schenauer, Matthew R. ; Flynn, Gregory C. ; Goetze, Andrew M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-8b280ec8c549ef37c3bda759a387e17bd268228453e88bd7f8322fccf1edbc733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Amino Acid Sequence</topic><topic>Biological Therapy</topic><topic>Chromatography, Liquid</topic><topic>detection limit</topic><topic>drugs</topic><topic>enzyme-linked immunosorbent assay</topic><topic>Escherichia coli</topic><topic>Escherichia coli - metabolism</topic><topic>Escherichia coli Proteins - metabolism</topic><topic>Host cell proteins</topic><topic>Humans</topic><topic>liquid chromatography</topic><topic>Mass spectrometry</topic><topic>Mass Spectrometry - methods</topic><topic>Molecular Sequence Data</topic><topic>patients</topic><topic>peptides</topic><topic>Peptides - analysis</topic><topic>Peptides - chemistry</topic><topic>proteins</topic><topic>Proteins - analysis</topic><topic>Proteins - chemistry</topic><topic>Quantification</topic><topic>Receptors, Fc - metabolism</topic><topic>Recombinant Fusion Proteins - metabolism</topic><topic>Reference Standards</topic><topic>risk</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schenauer, Matthew R.</creatorcontrib><creatorcontrib>Flynn, Gregory C.</creatorcontrib><creatorcontrib>Goetze, Andrew M.</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Analytical biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schenauer, Matthew R.</au><au>Flynn, Gregory C.</au><au>Goetze, Andrew M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification and quantification of host cell protein impurities in biotherapeutics using mass spectrometry</atitle><jtitle>Analytical biochemistry</jtitle><addtitle>Anal Biochem</addtitle><date>2012-09-15</date><risdate>2012</risdate><volume>428</volume><issue>2</issue><spage>150</spage><epage>157</epage><pages>150-157</pages><issn>0003-2697</issn><eissn>1096-0309</eissn><abstract>Residual host cell proteins (HCPs) in biotherapeutics can present potential safety risks to patients or compromise product stability. As such, their levels are typically monitored using a multicomponent HCP enzyme-linked immunosorbent assay (ELISA) to ensure adequate removal. However, it is not possible to guarantee ELISA coverage of every possible HCP impurity, and the specific HCPs remaining following purification are rarely identified. In the current study, we characterized the ability of an advanced two-dimensional liquid chromatography/mass spectrometry platform (2D–LC/MSE) to identify and quantify known low-level spiked protein impurities in a therapeutic peptide Fc fusion protein. The label-free quantification procedure based on the “top 3” intensity tryptic peptides per protein was applied and improved on for this application. Limits of detection for unknown HCPs were approximated from the spiked protein data along with estimates for the quantitative accuracy of the method. In all, we established that most protein impurities present at 13±4ppm can be identified with a quantitative error of less than 2-fold using the more sensitive of two tested method formats. To conclude the study, we characterized all detectable Escherichia coli proteins present in this Fc fusion protein drug substance and discuss future applications of the method.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>22640604</pmid><doi>10.1016/j.ab.2012.05.018</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-2697
ispartof Analytical biochemistry, 2012-09, Vol.428 (2), p.150-157
issn 0003-2697
1096-0309
language eng
recordid cdi_proquest_miscellaneous_1032888846
source ScienceDirect Freedom Collection 2022-2024
subjects Amino Acid Sequence
Biological Therapy
Chromatography, Liquid
detection limit
drugs
enzyme-linked immunosorbent assay
Escherichia coli
Escherichia coli - metabolism
Escherichia coli Proteins - metabolism
Host cell proteins
Humans
liquid chromatography
Mass spectrometry
Mass Spectrometry - methods
Molecular Sequence Data
patients
peptides
Peptides - analysis
Peptides - chemistry
proteins
Proteins - analysis
Proteins - chemistry
Quantification
Receptors, Fc - metabolism
Recombinant Fusion Proteins - metabolism
Reference Standards
risk
title Identification and quantification of host cell protein impurities in biotherapeutics using mass spectrometry
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T20%3A46%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20and%20quantification%20of%20host%20cell%20protein%20impurities%20in%20biotherapeutics%20using%20mass%20spectrometry&rft.jtitle=Analytical%20biochemistry&rft.au=Schenauer,%20Matthew%20R.&rft.date=2012-09-15&rft.volume=428&rft.issue=2&rft.spage=150&rft.epage=157&rft.pages=150-157&rft.issn=0003-2697&rft.eissn=1096-0309&rft_id=info:doi/10.1016/j.ab.2012.05.018&rft_dat=%3Cproquest_cross%3E1032888846%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c440t-8b280ec8c549ef37c3bda759a387e17bd268228453e88bd7f8322fccf1edbc733%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1032888846&rft_id=info:pmid/22640604&rfr_iscdi=true